Targeted localized use of therapeutic antibodies: A review of non-systemic, topical and oral applications

Critical Reviews in Biotechnology

Volumn 36, Issue 3, 2016, Pages 506-520

  Jones, Russell G A ^a   Martino, Angela ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antibiotic resistance; antibody; antitoxin; clinical; disease; gastrointestinal; immunoglobulin; monoclonal; peroral; polyclonal

Indexed keywords

ANTIBIOTICS; COST REDUCTION; COSTS; DERMATOLOGY; DISEASES; ENZYME INHIBITION; SKIN; TOXIC MATERIALS; VIRUSES;

ANTIBIOTIC RESISTANCE; ANTITOXIN; CLINICAL; GASTROINTESTINAL; IMMUNOGLOBULIN; MONOCLONAL; PERORAL; POLYCLONAL;

ANTIBODIES;

ANTIBODY; BEVACIZUMAB; EYE DROPS; IPILIMUMAB; RANIBIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGE RELATED MACULAR DEGENERATION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BLOOD VOLUME; CORNEA NEOVASCULARIZATION; CROHN DISEASE; DERMATITIS; DRUG COST; DRUG USE; ENCAPSULATION; ENZYME INHIBITION; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HUMAN; LOCAL THERAPY; MONARTHRITIS; NEOPLASM; NOROVIRUS; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; PERITUMORAL DRUG ADMINISTRATION; PERSISTENT INFLAMMATORY MONOARTHRITIS; PH; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; ROTAVIRUS; SYSTEMIC CIRCULATION; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; MOUSE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; HUMANS; MICE;

EID: 84962362266     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2014.992388     Document Type: Review

References (219)

1. Abbott WM, Snow M, Eckersley S, et al. (2013). Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFalpha Fab fragment and human TNFalpha. Biosci Rep, 33, e00060.
2. Ali T, Kaitha S, Mahmood S, et al. (2013). Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf, 5, 79-99.
3. Anfinsen CB. (1972). The formation and stabilization of protein structure. Biochem J, 128, 737-49.
4. A°rhem K. (1989). Maasai food symbolism: The cultural connotations of milk, meat, and blood in the pastoral maasai diet. Anthropos, 84, 1-23.
5. Ashcroft GS, Jeong MJ, Ashworth JJ, et al. (2012). Tumor necrosis factor-alpha (TNF-alpha) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen, 20, 38-49.
6. Asteria CR, Ficari F, Bagnoli S, et al. (2006). Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: A pilot study. Scand J Gastroenterol, 41, 1064-72.
7. Atreya R, Neumann H, Neufert C, et al. (2014). In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med, 20, 313-18.
8. Attia EA, Belal DM, El Samahy MH, El Hamamsy MH. (2014). A pilot trial using topical regular crystalline insulin vs. aqueous zinc solution for uncomplicated cutaneous wound healing: Impact on quality of life. Wound Repair Regen, 22, 52-7.
9. Balsari AL, Morelli D, Menard S, et al. (1994). Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J, 8, 226-30.
10. Balsari A, Rumio C, Morelli D, et al. (2001). Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. Br J Cancer, 85, 1964-7.
11. Barde C, Laffitte E, Campanelli A, et al. (2011). Intralesional infliximab in noninfectious cutaneous granulomas: Three cases of necrobiosis lipoidica. Dermatology, 222, 212-16.
12. Barekzi NA, Felts AG, Poelstra KA, et al. (2002). Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections. Pharm Res, 19, 1801-7.
13. Barnes GL, Doyle LW, Hewson PH, et al. (1982). A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet, 319, 1371-3.
14. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. (2011). Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA, 305, 1460-8.
15. Bashshur ZF, Bazarbachi A, Schakal A, et al. (2006). Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol, 142, 1-9.
16. Berdugo M, Larsen IV, Abadie C, et al. (2012). Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application. Antimicrob Agents Chemother, 56, 1390-402.
17. Berghman LR, Abi-Ghanem D, Waghela SD, Ricke SC. (2005). Antibodies: An alternative for antibiotics? Poult Sci, 84, 660-6.
18. Berry JD, Gaudet RG. (2011). Antibodies in infectious diseases: Polyclonals, monoclonals and niche biotechnology. N Biotechnol, 28, 489-501.
19. Bhol KC, Tracey DE, Lemos BR, et al. (2013). AVX-470: A novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis, 19, 2273-81.
20. Bhol KC, Erlich EC, Keane DM, et al. (2014). Effects of AVX-470m, an oral polyclonal anti-TNF antibody, on survival and biomarkers in a murine model of gastrointestinal acute radiation syndrome. Gastroenterology, 146, S-352.
21. Blum PM, Phelps DL, Ank BJ, et al. (1981). Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants. Pediatr Res, 15, 1256-60.
22. Boirie Y, Dangin M, Gachon P, et al. (1997). Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci USA, 94, 14930-5.
23. Boushaba R, Kumpalume P, Slater NKH. (2003). Kinetics of whole serum and prepurified IgG digestion by pepsin for F(ab0)2 manufacture. Biotechnol Prog, 19, 1176-82.
24. Braegger CP, Nicholls S, Murch SH, et al. (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339, 89-91.
25. Brereton HM, Taylor SD, Farrall A, et al. (2005). Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol, 89, 1205-9.
26. Brown WE, Wold F. (1973). Alkyl isocyanates as active-site-specific reagents for serine proteases. Identification of the active-site serine as the site of reaction. Biochemistry, 12, 835-40.
27. Brunser O, Espinoza J, Figueroa G, et al. (1992). Field trial of an infant formula containing anti-rotavirus and anti-Escherichia coli milk antibodies from hyperimmunized cows. J Pediatr Gastroenterol Nutr, 15, 63-72.
28. Brussow H, Hilpert H, Walther I, et al. (1987). Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol, 25, 982-6.
29. Burek-Kozlowska A, Morell A, Hunziker T. (1994). Topical immunoglobulin G in atopic dermatitis. Int Arch Allergy Immunol, 104, 104-6.
30. Carlander D, Kollberg H, Wejaker PE, Larsson A. (2000). Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res, 21, 1-6.
31. Casadevall A. (1999). Passive antibody therapies: Progress and continuing challenges. Clin Immunol, 93, 5-15.
32. Casadevall A. (2002). Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis, 8, 833-41.
33. Casadevall A, Pirofski LA. (2012). Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe, 11, 447-56.
34. Casadevall A, Dadachova E, Pirofski LA. (2004). Passive antibody therapy for infectious diseases. Nat Rev Microbiol, 2, 695-703.
35. Casswall TH, Sarker SA, Faruque SM, et al. (2000). Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: A double-blind, placebo-controlled, clinical trial. Scand J Gastroenterol, 35, 711-18.
36. Chames P, Van Regenmortel M, Weiss E, Baty D. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol, 157, 220-33.
37. Chan AC, Carter PJ. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 10, 301-16.
38. Charles F, Camilleri M, Phillips SF, et al. (1995). Scintigraphy of the whole gut: Clinical evaluation of transit disorders. Mayo Clin Proc, 70, 113-18.
39. Church D, Elsayed S, Reid O, et al. (2006). Burn wound infections. Clin Microbiol Rev, 19, 403-34.
40. Code of Federal Regulations. (2014). Title 21: Food and drugs. Washington, DC: Government Printing Office, USA.
41. Collins PJ, Houghton LA, Read NW, et al. (1991). Role of the proximal and distal stomach in mixed solid and liquid meal emptying. Gut, 32, 615-19.
42. Copelan EA, Bechtel TP, Klein JP, et al. (1994). Controlled trial of orally administered immunoglobulin following bone marrow transplantation. Bone Marrow Transplant, 13, 87-91.
43. Couzin-Frankel J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. Science, 342, 1432-3.
44. Crabb JH. (1998). Antibody-based immunotherapy of cryptosporidiosis. Adv Parasitol, 40, 121-49.
45. Cumberlege GI. (1911). Administration of serum by the mouth. Br Med J, 2, 108.
46. Cunningham-Rundles C, Zhuo Z, Griffith B, Keenan J. (1992). Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation. J Immunol Methods, 152, 177-90.
47. da Cunha AP, Weiner HL. (2012). Induction of immunological tolerance by oral anti-CD3. Clin Dev Immunol, 2012, e425021.
48. Davidson GP, Whyte PB, Daniels E, et al. (1989). Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet, 2, 709-12.
49. Degen LP, Phillips SF. (1996). Variability of gastrointestinal transit in healthy women and men. Gut, 39, 299-305.
50. Den Hoed CM, De Vries AC, Mensink PB, et al. (2011). Bovine antibodybased oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial. Can J Gastroenterol, 25, 207-13.
51. Dixon FJ, Kuhns W, Weigle WO, Taylor P. (1959). The lack of absorption of ingested bovine antibody in humans. J Immunol, 83, 437-41.
52. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. (2002). Singledomain antibody fragments with high conformational stability. Protein Sci, 11, 500-15.
53. Dvorackova K, Rabiskova M, Gajdziok J, et al. (2010). Coated capsules for drug targeting to proximal and distal part of human intestine. Acta Pol Pharm, 67, 191-9.
54. Ebina T, Sato A, Umezu K, et al. (1985). Prevention of rotavirus infection by oral administration of cow colostrum containing antihumanrotavirus antibody. Med Microbiol Immunol, 174, 177-85.
55. Eibl MM, Wolf HM, Furnkranz H, Rosenkranz A. (1988). Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med, 319, 1-7.
56. Ermolenko DN, Zherdev AV, Dzantiev BB. (2004). Antibodies as specific chaperones. Biochemistry (Mosc), 69, 1233-8.
57. Evans CH, Kraus VB, Setton LA. (2014). Progress in intra-articular therapy. Nat Rev Rheumatol, 10, 11-22.
58. Evenepoel P, Geypens B, Luypaerts A, et al. (1998). Digestibility of cooked and raw egg protein in humans as assessed by stable isotope techniques. J Nutr, 128, 1716-22.
59. Farag N, Mahran L, Abou-Aisha K, El-Azizi M. (2013). Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur J Clin Microbiol Infect Dis, 32, 1149-60.
60. Faria AM, Weiner HL. (2005). Oral tolerance. Immunol Rev, 206, 232-59.
61. FDA. (2002). New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist, 67, 37988-98.
62. Felts AG, Giridhar G, Grainger DW, Slunt JB. (1999). Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Burns, 25, 415-23.
63. Felts AG, Grainger DW, Slunt JB. (2000). Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection. J Trauma, 49, 873-8.
64. Ferrara N, Damico L, Shams N, et al. (2006). Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina, 26, 859-70.
65. Ferrari G, Bignami F, Giacomini C, et al. (2013). Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci, 54, 1680-8.
66. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. (2009). Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: A pilot study. Rheumatol Int, 29, 961-5.
67. Fisher BA, Keat A. (2006). Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis? J Rheumatol, 33, 1934-5.
68. Florescu DF, Hill LA, McCartan MA, Grant W. (2008). Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr Transplant, 12, 372-5.
69. Florescu DF, Hermsen ED, Kwon JY, et al. (2011). Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients? Pediatr Transplant, 15, 718-21.
70. Fong AH, Lai TY. (2013). Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging, 8, 467-83.
71. Fontana A, De Laureto PP, Spolaore B, et al. (2004). Probing protein structure by limited proteolysis. Acta Biochim Pol, 51, 299-321.
72. Ford AC, Peyrin-Biroulet L. (2013). Opportunistic infections with antitumor necrosis factor-alpha therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials. Am J Gastroenterol, 108, 1268-76.
73. Fransen MF, Van Der Sluis TC, Ossendorp F, et al. (2013). Controlled local delivery of CTLA-4 blocking antibody induces CD8+T-celldependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res, 19, 5381-9.
74. Furrer E, Berdugo M, Stella C, et al. (2009). Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci, 50, 771-8.
75. Galloway JB, Hyrich KL, Mercer LK, et al. (2011). Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford), 50, 124-31.
76. Gomez HF, Miller MJ, Trachy JW, et al. (1999). Intradermal antiloxosceles Fab fragments attenuate dermonecrotic arachnidism. Acad Emerg Med, 6, 1195-202.
77. Guarino A, Canani RB, Russo S, et al. (1994). Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics, 93, 12-16.
78. Hammarstrom V, Smith CI, Hammarstrom L. (1993). Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet, 341, 1036.
79. Hammarstrom L, Gardulf A, Hammarstrom V, et al. (1994). Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev, 139, 43-70.
80. Hansen S. (2013). Product discovery and development. Topical antibodies. BioCentury, 9, 7.
81. Harmsen MM, De Haard HJ. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 77, 13-22.
82. Harmsen MM, Van Solt CB, Van Zijderveld-van Bemmel AM, et al. (2006). Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol, 72, 544-51.
83. Hilpert H, Brussow H, Mietens C, et al. (1987). Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis, 156, 158-66.
84. Hodi FS, O'Day SJ, McDermott DF, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711-23.
85. Horie K, Horie N, Abdou AM, et al. (2004). Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci, 87, 4073-9.
86. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42.
87. Husby S, Mestecky J, Moldoveanu Z, et al. (1994). Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol, 152, 4663-70.
88. Hussack G, Arbabi-Ghahroudi M, Van Faassen H, et al. (2011). Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem, 286, 8961-76.
89. Hussack G, Tanha J. (2010). Toxin-specific antibodies for the treatment of Clostridium difficile: Current status and future perspectives. Toxins (Basel), 2, 998-1018.
90. Hussack G, Mackenzie CR, Tanha J. (2012). Characterization of singledomain antibodies with an engineered disulfide bond. Methods Mol Biol, 911, 417-29.
91. Ibekwe VC, Fadda HM, McConnell EL, et al. (2008). Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res, 25, 1828-35.
92. Ibrahim SM, Rahman AK, Isoda R, et al. (2008). In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine, 26, 2073-80.
93. Imoto T, Yamada H, Ueda T. (1986). Unfolding rates of globular proteins determined by kinetics of proteolysis. J Mol Biol, 190, 647-9.
94. Jackson JE, Kopecki Z, Adams DH, Cowin AJ. (2012). Flii neutralizing antibodies improve wound healing in porcine preclinical studies. Wound Repair Regen, 20, 523-36.
95. Jemmerson R, Paterson Y. (1986). Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science, 232, 1001-4.
96. Jones RGA, Landon J. (2002). Enhanced pepsin digestion: A novel process for purifying antibody F(ab0)2 fragments in high yield from serum. J Immunol Methods, 263, 57-74.
97. Jones RGA, Landon J. (2003). A protocol for 'enhanced pepsin digestion': A step by step method for obtaining pure antibody fragments in high yield from serum. J Immunol Methods, 275, 239-50.
98. Jones RGA, Marks JD. (2013). Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol, 62, 828-35.
99. Jones RGA, Lee L, Landon J. (1999). The effects of specific antibody fragments on the 'irreversible' neurotoxicity induced by Brown snake (Pseudonaja) venom. Br J Pharmacol, 126, 581-4.
100. Kanfer EJ, Abrahamson G, Taylor J, et al. (1994). Severe rotavirusassociated diarrhoea following bone marrow transplantation: Treatment with oral immunoglobulin. Bone Marrow Transplant, 14, 651-2.
101. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet, 49, 493-507.
102. Kelly CP, Chetham S, Keates S, et al. (1997). Survival of anti- Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother, 41, 236-41.
103. Kitamura K, Takahashi T, Kotani T, et al. (1992). Local administration of monoclonal antibody-drug conjugate: A new strategy to reduce the local recurrence of colorectal cancer. Cancer Res, 52, 6323-8.
104. Klager AJ, Buchi ER, Osusky R, et al. (1993). Topical immunoglobulins for epithelial herpes simplex keratitis. Ophthalmologica, 207, 78-81.
105. Kobayashi T, Ametani A, Yamauchi K, Kaminogawa S. (1991). Differences in defining residues relevant to antibody binding by ELISA and proteolysis protection at the level of peptide antigenic determinants. Biochim Biophys Acta, 1077, 11-18.
106. Kollberg H, Carlander D, Olesen H, et al. (2003). Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: A phase I feasibility study. Pediatr Pulmonol, 35, 433-40.
107. Kopecki Z, Ruzehaji N, Turner C, et al. (2013). Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. J Invest Dermatol, 133, 1008-16.
108. Kovacs-Nolan J, Mine Y. (2012). Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol, 3, 163-82.
109. Kovacs-Nolan J, Mine Y. (2005). Microencapsulation for the gastric passage and controlled intestinal release of immunoglobulin Y. J Immunol Methods, 296, 199-209.
110. Kozuch PL, Hanauer SB. (2008). Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol, 14, 354-77.
111. Krizova D, Vokrojova M, Liehneova K, Studeny P. (2014). Treatment of corneal neovascularization using anti-VEGF bevacizumab. J Ophthalmol, 2014, e178132.
112. Krogdahl A, Holm H. (1981). Soybean proteinase inhibitors and human proteolytic enzymes: Selective inactivation of inhibitors by treatment with human gastric juice. J Nutr, 111, 2045-51.
113. Kumpalume P, Boushaba R, Jones RGA, Slater NKH. (2002). Facile F(ab0)2 manufacturing: Strategies for the production of snake antivenoms. Food Bioprod Process, 80, 88-97.
114. Lalazar A, Loyter A. (1979). Involvement of spectrin in membrane fusion: Induction of fusion in human erythrocyte ghosts by proteolytic enzymes and its inhibition by antispectrin antibody. Proc Natl Acad Sci USA, 76, 318-22.
115. Landon J, Smith DS. (2003). Merits of sheep antisera for antivenom manufacture. Toxin Rev, 22, 15-22.
116. Larsson A, Carlander D. (2003). Oral immunotherapy with yolk antibodies to prevent infections in humans and animals. Ups J Med Sci, 108, 129-40.
117. Lebwohl M, Ting PT, Koo JY. (2005). Psoriasis treatment: Traditional therapy. Ann Rheum Dis, 64, 83-6.
118. Lichtlen P, Lam TT, Nork TM, et al. (2010). Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: Comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci, 51, 4738-45.
119. Liu F, Basit AW. (2010). A paradigm shift in enteric coating: Achieving rapid release in the proximal small intestine of man. J Control Release, 147, 242-5.
120. Liu F, Moreno P, Basit AW. (2010). A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract. Eur J Pharm Biopharm, 74, 311-15.
121. Losonsky GA, Johnson JP, Winkelstein JA, Yolken RH. (1985). Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest, 76, 2362-7.
122. MacLennan C, Dunn G, Huissoon AP, et al. (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet, 363, 1509-13.
123. Madsen JL. (1992). Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci, 37, 1548-53.
124. Mahe S, Roos N, Benamouzig R, et al. (1996). Gastrojejunal kinetics and the digestion of [15N]beta-lactoglobulin and casein in humans: The influence of the nature and quantity of the protein. Am J Clin Nutr, 63, 546-52.
125. Manca F, Fenoglio D, Li PG, et al. (1991). Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med, 173, 37-48.
126. Marabelle A, Kohrt H, Levy R. (2013a). Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity. Clin Cancer Res, 19, 5261-3.
127. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. (2013b). Depleting tumorspecific Tregs at a single site eradicates disseminated tumors. J Clin Invest, 123, 2447-63.
128. Marabelle A, Kohrt H, Caux C, Levy R. (2014). Intratumoral immunization: A new paradigm for cancer therapy. Clin Cancer Res, 20, 1747-56.
129. Marasco WA, Sui J. (2007). The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol, 25, 1421-34.
130. Mattila E, Anttila VJ, Broas M, et al. (2008). A randomized, doubleblind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis, 40, 702-8.
131. Meddeb-Mouelhi F, Bouhaouala-Zahar B, Benlasfar Z, et al. (2003). Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon, 42, 785-91.
132. Mayberry JF, Lobo A, Ford AC, Thomas A. (2013). NICE clinical guideline (CG152): The management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther, 37, 195-203.
133. Meyer T, Ullrich R, Zeitz M. (2012). Oral tolerance induction in humans. Exp Mol Pathol, 93, 449-54.
134. MHRA. (2014). Rules and guidance for pharmaceutical manufacturers and distributors 2014 the orange guide.
135. Mietens C, Keinhorst H, Hilpert H, et al. (1979). Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins. Eur J Pediatr, 132, 239-52.
136. Mojaverian P, Ferguson RK, Vlasses PH, et al. (1985). Estimation of gastric residence time of the Heidelberg capsule in humans: Effect of varying food composition. Gastroenterology, 89, 392-7.
137. Morelli D, Menard S, Colnaghi MI, Balsari A. (1996). Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy- induced gastrointestinal toxicity in mice. Cancer Res, 56, 2082-5.
138. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology, 113, 2002-12.
139. Neri P, Tokoro S, Kobayashi R, et al. (2011). Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxinmediated diseases. PLoS One, 6, e26526.
140. Newcombe C, Newcombe AR. (2007). Antibody production: Polyclonalderived biotherapeutics. J Chromatogr B, 848:2-7.
141. NICE. (2008). Adalimumab for the treatment of adults with psoriasis (TA146). Available from: Http://www.nice.org.uk/guidance/TA146 [last accessed 20 Jul 2014].
142. NICE. (2009). Rheumatoid arthritis (CG79). Available from: Http://www.nice.org.uk/guidance/CG79 [last accessed 20 Jul 2014].
143. Nikas SN, Temekonidis TI, Zikou AK, et al. (2004). Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: A pilot study. Ann Rheum Dis, 63, 102-3.
144. Nilsson E, Kollberg H, Johannesson M, et al. (2007). More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: A case report. J Med Food, 10, 375-8.
145. Nilsson E, Larsson A, Olesen HV, et al. (2008). Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol, 43, 892-9.
146. Nord J, Ma P, DiJohn D, et al. (1990). Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS, 4, 581-4.
147. Numan SC, Veldkamp P, Kuijper EJ, et al. (2007). Clostridium difficileassociated diarrhoea: Bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut, 56, 888-9.
148. Ohtani T, Habu M, Khanal A, et al. (2012). Local effects of intra-articular injection of anti-rabbit tumor necrosis factor alpha monoclonal antibody in antigen-induced arthritis of the rabbit temporomandibular joint. J Oral Pathol Med, 41, 96-105.
149. Ohtani S, Shirasu K, Ogawara K, et al. (2003). Evaluation of inhibitory activity of casein on proteases in rat intestine. Pharm Res, 20, 611-17.
150. Okhuysen PC, Chappell CL, Crabb J, et al. (1998). Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum. Clin Infect Dis, 26, 1324-9.
151. Ottiger M, Thiel MA, Feige U, et al. (2009). Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci, 50, 779-86.
152. Pacyna J, Siwek K, Terry SJ, et al. (2001). Survival of rotavirus antibody activity derived from bovine colostrum after passage through the human gastrointestinal tract. J Pediatr Gastroenterol Nutr, 32, 162-7.
153. Pant N, Hultberg A, Zhao Y, et al. (2006). Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis, 194, 1580-8.
154. Paton DM. (1906). Serum therapy by the mouth. Br Med J, 1, 1032.
155. Petschow BW, Talbott RD. (1994). Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr, 19, 228-35.
156. Petsoglou C, Balaggan KS, Dart JK, et al. (2013). Subconjunctival bevacizumab induces regression of corneal neovascularisation: A pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol, 97, 28-32.
157. Pinho E, Grootveld M, Soares G, Henriques M. (2014). Cyclodextrinbased hydrogels toward improved wound dressings. Crit Rev Biotechnol, 34, 328-37.
158. Playford RJ, Woodman AC, Clark P, et al. (1993). Effect of luminal growth factor preservation on intestinal growth. Lancet, 341, 843-8.
159. Pocklington T, Jeffery J. (1969). Competition of two substrates for a single enzyme. A simple kinetic theorem exemplified by a hydroxy steroid dehydrogenase reaction. Biochem J, 112, 331-4.
160. Poelstra KA, Barekzi NA, Slunt JB, et al. (2000). Surgical irrigation with pooled human immunoglobulin G to reduce post-operative spinal implant infection. Tissue Eng, 6, 401-11.
161. Porter RR. (1959). The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem J, 73, 119-26.
162. Powers JC, Harley AD, Myers DV. (1977). Subsite specificity of porcine pepsin. Adv Exp Med Biol, 95, 141-57.
163. Rahman S, Higo-Moriguchi K, Htun KW, et al. (2012). Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine, 30, 4661-9.
164. Rao RK, Baker RD, Baker SS. (1998). Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides, 19, 495-504.
165. Reichert JM. (2011). Antibody-based therapeutics to watch in 2011. MAbs, 3, 76-99.
166. Reichert JM. (2012). Marketed therapeutic antibodies compendium. MAbs, 4, 413-15.
167. Reseland JE, Holm H, Jacobsen MB, et al. (1996). Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J Nutr, 126, 634-42.
168. Roos N, Mahe S, Benamouzig R, et al. (1995). 15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine. J Nutr, 125, 1238-44.
169. Roy FH, Fraunfelder FW, Fraunfelder FT. (2008). Roy and Fraunfelder's current ocular therapy. 6th ed. London: Saunders Imprint.
170. Ruzehaji N, Kopecki Z, Melville E, et al. (2014). Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes. Diabetologia, 57, 402-12.
171. Salemi S, Markovic M, Martini G, D'Amelio R. (2014). The expanding role of therapeutic antibodies. Int Rev Immunol. Published online ahead of print 28 January 2014, doi:10.3109/08830185.2013.863304.
172. Sandin LC, Eriksson F, Ellmark P, et al. (2014a). Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology, 3, e27614.
173. Sandin LC, Orlova A, Gustafsson E, et al. (2014b). Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res, 2, 80-90.
174. Sands BE, Anderson FH, Bernstein CN, et al. (2004). Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 350, 876-85.
175. Sarker SA, Casswall TH, Juneja LR, et al. (2001). Randomized, placebocontrolled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr, 32, 19-25.
176. Sarker SA, Jakel M, Sultana S, et al. (2013). Anti-rotavirus protein reduces stool output in infants with diarrhea: A randomized placebocontrolled trial. Gastroenterology, 145, 740-8.
177. Schade R, Calzado EG, Sarmiento R, et al. (2005). Chicken egg yolk antibodies (IgY-technology): A review of progress in production and use in research and human and veterinary medicine. Altern Lab Anim, 33, 129-54.
178. Schlamowitz M, Peterson LU. (1959). Studies on the optimum pH for the action of pepsin on ''native'' and denatured bovine serum albumin and bovine hemoglobin. J Biol Chem, 234, 3137-45.
179. Schmidt P, Wiedemann V, Kuhlmann R, et al. (1989). Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases. II. In vitro studies on gastric and enteric digestion of egg yolk antibodies specific against pathogenic Escherichia coli strains. Zentralbl Veterinarmed B, 36, 619-28.
180. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. (2007). Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med, 357, 239-50.
181. Scott AM, Allison JP, Wolchok JD. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunol, 12, 1-8.
182. Shone C, Landon J. (2014). Antibodies to Clostridium difficile toxins. Patent US8709428 B2, USA.
183. Shone C, Roberts A, Landon J. (2013). Therapies for preventing or suppressing Clostridium difficile infection. Patent application US20130004561 A1.
184. Splittgerber AG. (1983). Simplified treatment of two-substrate enzyme kinetics. J Chem Educ, 60, 651-5.
185. Steinbrook R. (2006). The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med, 355, 1409-12.
186. Stevens NE, Fraser CK, Alsharifi M, et al. (2013). An empirical approach towards the efficient and optimal production of influenzaneutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT is functionally superior to Freund's adjuvant. PLoS One, 8, e68895.
187. Stevenson W, Cheng SF, Dastjerdi MH, et al. (2012). Corneal neovascularization and the utility of topical VEGF inhibition: Ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf, 10, 67-83.
188. Streit M, Beleznay Z, Braathen LR. (2006). Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J, 3, 171-9.
189. Suckau D, Kohl J, Karwath G, et al. (1990). Molecular epitope identification by limited proteolysis of an immobilized antigenantibody complex and mass spectrometric peptide mapping. Proc Natl Acad Sci USA, 87, 9848-52.
190. Suzuki H, Nomura S, Masaoka T, et al. (2004). Effect of dietary anti- Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther, 20, 185-92.
191. Syed A, Cross RK, Flasar MH. (2013). Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients. Am J Gastroenterol, 108, 583-93.
192. Tacket CO, Losonsky G, Link H, et al. (1988). Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med, 318, 1240-3.
193. Tacket CO, Binion SB, Bostwick E, et al. (1992). Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg, 47, 276-83.
194. Tappenden P, Jones R, Paisley S, Carroll C. (2007). Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess, 11, 1-4.
195. Taxonera C, Schwartz DA, Garcia-Olmo D. (2009). Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol, 15, 4263-72.
196. Teh YH, Kavanagh TA. (2010). High-level expression of Camelid nanobodies in Nicotiana benthamiana. Transgenic Res, 19, 575-86.
197. Teich N, Klugmann T. (2014). Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis, 8, 85-6.
198. Thakral S, Thakral NK, Majumdar DK. (2013). Eudragit: A technology evaluation. Expert Opin Drug Deliv, 10, 131-49.
199. Thiel MA, Coster DJ, Standfield SD, et al. (2002). Penetration of engineered antibody fragments into the eye. Clin Exp Immunol, 128, 67-74.
200. Thiel MA, Wild A, Schmid MK, et al. (2013). Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology, 120, 1403-8.
201. Tjellstrom B, Stenhammar L, Magnusson KE, Sandqvist T. (1997). Oral immunoglobulin treatment in Crohn's disease. Acta Paediatr, 86, 221-3.
202. Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. (1993). Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet, 341, 701-2.
203. Tollemar J, Gross N, Dolgiras N, et al. (1999). Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant, 23, 283-90.
204. Tonelli F, Giudici F, Asteria CR. (2012). Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: A pilot study. Dis Colon Rectum, 55, 870-5.
205. Urech DM, Feige U, Ewert S, et al. (2010). Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF alpha single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis, 69, 443-9.
206. Van Dissel JT, De Groot N, Hensgens CM, et al. (2005). Bovine antibodyenriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: Preclinical and preliminary clinical data. J Med Microbiol, 54, 197-205.
207. Vandenbroucke K, De Haard H, Beirnaert E, et al. (2010). Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol, 3, 49-56.
208. Von Behring E. (1901). Nobel Lecture: Serum therapy in therapeutics and medical science. Available from Nobelprize.org. http://www. nobelprize.org/nobel-prizes/medicine/laureates/1901/behring-lecture. html [last accessed 1 Jul 2014].
209. Waaga-Gasser AM, Gasser M, Stock M, et al. (2009). Oral immunoglobulin induces mononuclear cell apoptosis in patients suffering from idiopathic chronic pain syndrome: Results from a pilot study. Int J Clin Pharmacol Ther, 47, 421-33.
210. Wang W, Wang EQ, Balthasar JP. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther, 84, 548-58.
211. Warny M, Fatimi A, Bostwick EF, et al. (1999). Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut, 44, 212-17.
212. Weiner C, Pan Q, Hurtig M, et al. (1999). Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol, 116, 193-205.
213. West RL, Zelinkova Z, Wolbink GJ, et al. (2008). Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther, 28, 1122-6.
214. Wicher K, Zabek J, Wicher V. (1992). Effect of passive immunization with purified specific or cross-reacting immunoglobulin G antibodies against Treponema pallidum on the course of infection in guinea pigs. Infect Immunol, 60, 3217-23.
215. Williams KA, Irani YD, Klebe S. (2013). Novel therapeutic approaches for corneal disease. Discov Med, 15, 291-9.
216. Worledge KL, Godiska R, Barrett TA, Kink JA. (2000). Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci, 45, 2298-305.
217. Xian CJ, Shoubridge CA, Read LC. (1995). Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. J Endocrinol, 146, 215-25.
218. Xu ZQ, Flavin MT, Flavin J. (2014). Combating multidrug-resistant Gram-negative bacterial infections. Expert Opin Investig Drugs, 23, 163-82.
219. Zaidi TS, Zaidi T, Pier GB, Priebe GP. (2012). Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immunol, 80, 3706-12.